Karakoç Metin Deniz
Denizli State Hospital, Zafer Gökşin Oncology Centre, Denizli, Turkey.
Turk J Pharm Sci. 2017 Dec;14(3):304-310. doi: 10.4274/tjps.25238. Epub 2017 Nov 20.
As a cancer treatment option, chemotherapy costs make up a large part of the budgets of social insurance foundations and related expenditures are increasing continuously annually. Cost saving and waste minimizing strategies are required to reduce the expenditures in the field of oncology. The study aimed to reduce the amount of wasted antineoplastic drugs and medical supply consumption.
The study explains why vials with a larger size and drugs in liquid form should be preferred over various smaller sizes and powder forms of antineoplastic preparations.
Amounts of drug wastage, vial adaptor, and transfer set consumption data were recorded regularly for a period of seven months. The average vial adaptor consumption per patient in the last three months decreased from 5 to 3.3. The preference of liquid forms as much as possible instead of powder forms, which has a shorter stability time after dilution, and the choice of larger package sizes of frequently used drugs decreased vial adaptor consumption. Potential savings were calculated as around 31.660 USD annually. Costs of total wasted doses were 8.699.87 USD, and the whole antineoplastic drug consumption was 515.500 USD during the study. A decrease of 0.58 USD was observed per capita when the first and last three-month periods were compared in terms of waste costs.
These values indicate that the reduction of wasted drugs have potential annual savings of 3.375 USD. It is shown that total potential savings of 35.000 USD could be made per year. By implementing the same principles in all hospitals in Turkey, approximately 2.8 million USD could be made annually. The pharmaceutical industry and hospital pharmacists have important responsibilities in this issue.
作为一种癌症治疗选择,化疗费用在社会保险基金预算中占很大一部分,且相关支出每年持续增加。需要采取节约成本和减少浪费的策略来降低肿瘤学领域的支出。本研究旨在减少抗肿瘤药物的浪费量和医疗用品消耗。
该研究解释了为何应优先选择较大规格的安瓿瓶以及液体制剂形式的药物,而非各种较小规格和粉末形式的抗肿瘤制剂。
在七个月的时间里定期记录药物浪费量、安瓿瓶适配器和输液器消耗数据。过去三个月每位患者的安瓿瓶适配器平均消耗量从5个降至3.3个。尽可能选择液体制剂而非稀释后稳定性较短的粉末制剂,以及选择常用药物的较大包装规格,减少了安瓿瓶适配器的消耗。经计算,每年潜在节约约31,660美元。研究期间,总浪费剂量的成本为8,699.87美元,抗肿瘤药物总消耗量为515,500美元。在浪费成本方面,比较第一个和最后三个月时,人均浪费成本下降了0.58美元。
这些数据表明,减少药物浪费每年可潜在节约3,375美元。结果显示每年可实现总计35,000美元的潜在节约。通过在土耳其所有医院实施相同原则,每年可节约约280万美元。制药行业和医院药剂师在这个问题上负有重要责任。